Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients

European Neurology

Volumn 61, Issue 3, 2009, Pages 177-182

  Portaccio, E ^a   Zipoli, V ^a   Siracusa, G ^a   Sorbi, S ^a   Amato, M P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Interferon beta therapy; Long term response; Multiple sclerosis; Second line therapies

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; INTERFERON BETA SERINE; MITOXANTRONE;

ADULT; ARTICLE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PARAMETER; PRIORITY JOURNAL; RATING SCALE; TREATMENT DURATION;

ADULT; COHORT STUDIES; FEMALE; FORECASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; KAPLAN-MEIERS ESTIMATE; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; RECURRENCE; REGRESSION ANALYSIS; TREATMENT FAILURE;

EID: 58149168431     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000189271     Document Type: Article

References (23)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-661.
2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-1504.
3. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group: PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
5. Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L: Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007;259:104-108.
6. Coyle PK: Switching algorithms: from one immunomodulatory agent to another. J Neurol 2008;255(suppl 1):44-50.
7. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP: Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59:131-135.
8. Wingerchuk DM: Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol 2008;28:56-68.
9. Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M, et al: Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002;52:400-406.
10. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, et al: Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-189.
11. Rio J, Tintore M, Nos C, Tellez N, Galan I, Pelayo R, et al: Validation of clinical criteria for response to interferon-beta therapy. Mult Scler 2004;10(suppl 2):S237.
12. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E: Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-555.
13. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP: Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler 2006;12:281-286.
14. Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C, et al: Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006;253:287-293.
15. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, et al: Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352.
16. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
17. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
18. Schumacher GA, Beebe GW, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al: Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-568.
19. O'Rourke K, Walsh C, Antonelli G, Hutchinson M: Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007;13:336-342.
20. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N: Contribution of relapses to disability in multiple sclerosis. J Neurol 2008;255:280-287.
21. Martinez-Yelamos S, Martinez-Yelamos A, Martin Ozaeta G, Casado V, Carmona O, Arbizu T: Regression to the mean in multiple sclerosis. Mult Scler 2006;12:826-829.
22. Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, et al: Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1119-1127.
23. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, et al: MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:646-651.